Literature DB >> 4129049

[Glycerophosphatides and sphingolipids in normal white matter of multiple sclerosis brains (author's transl)].

H Woelk, P Borri.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4129049

Source DB:  PubMed          Journal:  Z Neurol        ISSN： 0012-1037


× No keyword cloud information.
  36 in total

1.  SEPARATION OF THE LIPIDS OF PHOTOSYNTHETIC TISSUES: IMPROVEMENTS IN ANALYSIS BY THIN-LAYER CHROMATOGRAPHY.

Authors:  B W NICHOLS
Journal:  Biochim Biophys Acta       Date:  1963-08-27

2.  Phosphorus assay in column chromatography.

Authors:  G R BARTLETT
Journal:  J Biol Chem       Date:  1959-03       Impact factor: 5.157

3.  Lipid chemistry of the brain in demyelinating diseases.

Authors:  J N CUMINGS
Journal:  Brain       Date:  1955       Impact factor: 13.501

4.  Myelin constituents of human central nervous system.

Authors:  J Clausen; I B Hansen
Journal:  Acta Neurol Scand       Date:  1970       Impact factor: 3.209

5.  [Effect of phospholipase A from snake venom on phosphatidylcholine, phosphatidylethanolamine and on the corresponding plasmalogens. Enzyme kinetic studies].

Authors:  H Woelk; H Debuch
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1971-10

6.  Lipids and proteins in multiple sclerosis white matter.

Authors:  B Gerstl; L F Eng; M Tavaststjerna; J K Smith; S L Kruse
Journal:  J Neurochem       Date:  1970-05       Impact factor: 5.372

7.  [Acid chromatography preparation of phosphatides from brain total lipid extracts].

Authors:  K Harzer; K Sandhoff; H Jatzkewitz
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1967-01

8.  Gangliosides and glycerophospholipids in multiple sclerosis white matter.

Authors:  Y Kishimoto; N S Radin; W W Tourtellotte; J A Parker; H H Itabashi
Journal:  Arch Neurol       Date:  1967-01

9.  [The lipids of several human tissues and organs].

Authors:  M Winterfeld; H Debuch
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1966

10.  Lipid studies in the blood and brain in multiple sclerosis and motor neurone disease.

Authors:  J N Cumings; R C Shortman; T Skrbic
Journal:  J Clin Pathol       Date:  1965-09       Impact factor: 3.411
View more
  8 in total

1.  [On the activity of phospholipase A2 compared with 1-alk-1'-enyl-2-acyl- and 1-alkyl-2-acyl-glycerophosphatides in multiple sclerosis (author's transl)].

Authors:  H Woelk; K Peiler-Ichikawa
Journal:  J Neurol       Date:  1974       Impact factor: 4.849

Review 2.  Is the myelin membrane abnormal in multiple sclerosis?

Authors:  D D Wood; M A Moscarello
Journal:  J Membr Biol       Date:  1984       Impact factor: 1.843

3.  [The glycerophospholipid content of the white matter of normal and MS brains (author's transl)].

Authors:  M Winterfeld; H Debuch
Journal:  J Neurol       Date:  1977-07-20       Impact factor: 4.849

4.  The fatty acid composition of major glycosphingolipids (cerebrosides and sulfatides) in human cerebral white matter measured by a simple micromethod.

Authors:  R Heipertz; H Pilz; W Scholz
Journal:  J Neurol       Date:  1976-07-15       Impact factor: 4.849

5.  On the effect of brain phospholipase A1 on specifically labelled glycerophospholipids in the course of subacute sclerosing panencephalitis.

Authors:  U J Morgott; H Woelk
Journal:  J Neurol       Date:  1975       Impact factor: 4.849

6.  On the activity of brain phospholipase A2 towards specifically labelled glycerophospholipids during subacute sclerosing panencephalitis.

Authors:  U Jakumeit-Morgott; H Woelk; K Kanig
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1975-05-28

7.  The fatty acid composition of sphingomyelin from adult human cerebral white matter and changes in childhood, senium and unspecific brain damage.

Authors:  R Heipertz; H Pilz; W Scholz
Journal:  J Neurol       Date:  1977-08-18       Impact factor: 4.849

8.  Investigations of the lipid metabolism of the white matter in multiple sclerosis: changes in glycero-phosphatides and lipid-splitting enzymes.

Authors:  I Neu; H Woelk
Journal:  Neurochem Res       Date:  1982-06       Impact factor: 3.996
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.